ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein
March 10, 2021JS201, developed by Junshi Biosciences, can simultaneously target PD-1 and TGF-β. -
CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein
March 08, 2021Recently, CMAB Biopharma (Suzhou) Inc's partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products ...
Pharma Sources Insight January 2025
